<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-02-25" updated="2019-12-02">
  <drugbank-id primary="true">DB11464</drugbank-id>
  <name>Sulfaquinoxaline</name>
  <description>Sulfaquinoxaline is a veterinary medicine which can be given to cattle and sheep to treat coccidiosis.It is available in Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as potential treatment of coccidiosis.</description>
  <cas-number>59-40-5</cas-number>
  <unii>WNW8115TM9</unii>
  <average-mass>300.336</average-mass>
  <monoisotopic-mass>300.068096338</monoisotopic-mass>
  <groups>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A8940</ref-id>
        <pubmed-id>5430695</pubmed-id>
        <citation>Righter HF, Worthington JM, Zimmerman HE Jr, Mercer HD: Tissue-residue depletion of sulfaquinoxaline in poultry. Am J Vet Res. 1970 Jun;31(6):1051-4.</citation>
      </article>
      <article>
        <ref-id>A8941</ref-id>
        <pubmed-id>451426</pubmed-id>
        <citation>Rutczynska-Skonieczna EM: [Detection of sulfaquinoxaline residues in eggs]. Rocz Panstw Zakl Hig. 1979;30(2):137-40.</citation>
      </article>
      <article>
        <ref-id>A8942</ref-id>
        <pubmed-id>847331</pubmed-id>
        <citation>Rutczynska-Skonieczna EM: [Detection of sulfaquinoxaline residues in poultry meat]. Rocz Panstw Zakl Hig. 1977;28(1):59-63.</citation>
      </article>
      <article>
        <ref-id>A8943</ref-id>
        <pubmed-id>5962189</pubmed-id>
        <citation>Kahn SG, Actor P: Enhancement of sulfaquinoxaline activity by nystatin. Poult Sci. 1966 May;45(3):581-2.</citation>
      </article>
      <article>
        <ref-id>A8944</ref-id>
        <pubmed-id>7174488</pubmed-id>
        <citation>Brown MJ, Wojcik B, Burgess EC, Smith GJ: Adverse reactions to sulfaquinoxaline in coyote pups--. J Am Vet Med Assoc. 1982 Dec 1;181(11):1419-20.</citation>
      </article>
      <article>
        <ref-id>A8945</ref-id>
        <pubmed-id>13349011</pubmed-id>
        <citation>Authors unspecified: VITAMIN K and sulfaquinoxaline poisoning in chickens. Nutr Rev. 1956 Aug;14(8):240-1.</citation>
      </article>
      <article>
        <ref-id>A8946</ref-id>
        <pubmed-id>20265822</pubmed-id>
        <citation>MUSHETT CW, SEELER AO: Hypoprothrombinemia resulting from the administration of sulfaquinoxaline. J Pharmacol Exp Ther. 1947 Sep;91(1):84-91.</citation>
      </article>
      <article>
        <ref-id>A8947</ref-id>
        <pubmed-id>13533778</pubmed-id>
        <citation>HAGEN KW Jr: The effects of continuous sulfaquinoxaline feeding on rabbit mortality. Am J Vet Res. 1958 Apr;19(71):494-6.</citation>
      </article>
      <article>
        <ref-id>A8948</ref-id>
        <pubmed-id>13444564</pubmed-id>
        <citation>STOWE CM, PALLESEN D, HARTMAN W: Studies on the pharmacology of sulfaquinoxaline in dairy cattle. Am J Vet Res. 1957 Jul;18(68):511-8.</citation>
      </article>
      <article>
        <ref-id>A8949</ref-id>
        <pubmed-id>10722074</pubmed-id>
        <citation>Berzas Nevado JJ, Castaneda Penalvo G, Guzman Bernardo FJ: Simultaneous determination of sulfaquinoxaline, sulfamethazine and pyrimethamine by liquid chromatography. J Chromatogr A. 2000 Feb 18;870(1-2):169-77.</citation>
      </article>
      <article>
        <ref-id>A8950</ref-id>
        <pubmed-id>23418152</pubmed-id>
        <citation>Le Fur C, Legeret B, de Sainte Claire P, Wong-Wah-Chung P, Sarakha M: Liquid chromatography/electrospray ionization quadrupole time-of-flight mass spectrometry for the analysis of sulfaquinoxaline byproducts formed in water upon solar light irradiation. Rapid Commun Mass Spectrom. 2013 Mar 30;27(6):722-30. doi: 10.1002/rcm.6507.</citation>
      </article>
      <article>
        <ref-id>A8951</ref-id>
        <pubmed-id>20810118</pubmed-id>
        <citation>Costi EM, Sicilia MD, Rubio S: Multiresidue analysis of sulfonamides in meat by supramolecular solvent microextraction, liquid chromatography and fluorescence detection and method validation according to the 2002/657/EC decision. J Chromatogr A. 2010 Oct 1;1217(40):6250-7. doi: 10.1016/j.chroma.2010.08.017. Epub 2010 Aug 13.</citation>
      </article>
      <article>
        <ref-id>A8952</ref-id>
        <pubmed-id>20673955</pubmed-id>
        <citation>De Liguoro M, Di Leva V, Gallina G, Faccio E, Pinto G, Pollio A: Evaluation of the aquatic toxicity of two veterinary sulfonamides using five test organisms. Chemosphere. 2010 Oct;81(6):788-93. doi: 10.1016/j.chemosphere.2010.07.003. Epub  2010 Jul 31.</citation>
      </article>
      <article>
        <ref-id>A8953</ref-id>
        <pubmed-id>23246932</pubmed-id>
        <citation>Herrera-Herrera AV, Hernandez-Borges J, Borges-Miquel TM, Rodriguez-Delgado MA: Dispersive liquid-liquid microextraction combined with ultra-high performance liquid chromatography for the simultaneous determination of 25 sulfonamide and quinolone antibiotics in water samples. J Pharm Biomed Anal. 2013 Mar 5;75:130-7. doi: 10.1016/j.jpba.2012.11.026. Epub 2012 Nov 23.</citation>
      </article>
      <article>
        <ref-id>A8954</ref-id>
        <pubmed-id>23126529</pubmed-id>
        <citation>Gaudin V, De Courville A, Hedou C, Rault A, Diomande SE, Creff-Froger C, Verdon E: Evaluation and validation of two microbiological tests for screening antibiotic residues in honey according to the European guideline for the validation of screening methods. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(2):234-43. doi: 10.1080/19440049.2012.738367. Epub 2012 Nov 6.</citation>
      </article>
      <article>
        <ref-id>A8955</ref-id>
        <pubmed-id>1106077</pubmed-id>
        <citation>Guinee P, Kruyt B: Use of an isolator system to study the selective pressure of sulfaquinoxalin-containing coccidiostats on Escherichia coli populations in chicks. Zentralbl Veterinarmed B. 1975 Nov;22(9):718-28.</citation>
      </article>
      <article>
        <ref-id>A8956</ref-id>
        <pubmed-id>20417329</pubmed-id>
        <citation>Sun L, Sun X, Du X, Yue Y, Chen L, Xu H, Zeng Q, Wang H, Ding L: Determination of sulfonamides in soil samples based on alumina-coated magnetite nanoparticles as adsorbents. Anal Chim Acta. 2010 Apr 30;665(2):185-92. doi: 10.1016/j.aca.2010.03.044. Epub 2010 Mar 27.</citation>
      </article>
      <article>
        <ref-id>A8957</ref-id>
        <pubmed-id>20726505</pubmed-id>
        <citation>Guo Y, Ngom B, Le T, Jin X, Wang L, Shi D, Wang X, Bi D: Utilizing three monoclonal antibodies in the development of an immunochromatographic assay for simultaneous detection of sulfamethazine, sulfadiazine, and sulfaquinoxaline residues in egg and chicken muscle. Anal Chem. 2010 Sep 15;82(18):7550-5. doi: 10.1021/ac101020y.</citation>
      </article>
      <article>
        <ref-id>A8958</ref-id>
        <pubmed-id>20217396</pubmed-id>
        <citation>Raich-Montiu J, Beltran JL, Prat MD, Granados M: Studies on the extraction of sulfonamides from agricultural soils. Anal Bioanal Chem. 2010 May;397(2):807-14. doi: 10.1007/s00216-010-3580-4. Epub 2010 Mar 10.</citation>
      </article>
      <article>
        <ref-id>A8959</ref-id>
        <pubmed-id>22202200</pubmed-id>
        <citation>Ghorab MM, Ragab FA, Heiba HI, El-Gazzar MG, El-Gazzar MG: Synthesis, in vitro anticancer screening and radiosensitizing evaluation of some new 4-[3-(substituted)thioureido]-N-(quinoxalin-2-yl)-benzenesulfonamide derivatives. Acta Pharm. 2011 Dec;61(4):415-25. doi: 10.2478/v10007-011-0040-4.</citation>
      </article>
      <article>
        <ref-id>A8960</ref-id>
        <pubmed-id>21644254</pubmed-id>
        <citation>Tolika EP, Samanidou VF, Papadoyannis IN: Development and validation of an HPLC method for the determination of ten sulfonamide residues in milk according to 2002/657/EC. J Sep Sci. 2011 Jul;34(14):1627-35. doi: 10.1002/jssc.201100171. Epub 2011 Jun 3.</citation>
      </article>
      <article>
        <ref-id>A8961</ref-id>
        <pubmed-id>21159362</pubmed-id>
        <citation>Wei R, Ge F, Huang S, Chen M, Wang R: Occurrence of veterinary antibiotics in animal wastewater and surface water around farms in Jiangsu Province, China. Chemosphere. 2011 Mar;82(10):1408-14. doi: 10.1016/j.chemosphere.2010.11.067. Epub 2010 Dec 14.</citation>
      </article>
      <article>
        <ref-id>A8962</ref-id>
        <pubmed-id>21563672</pubmed-id>
        <citation>Li H, Kijak PJ: Development of a quantitative multiclass/multiresidue method for 21 veterinary drugs in shrimp. J AOAC Int. 2011 Mar-Apr;94(2):394-406.</citation>
      </article>
      <article>
        <ref-id>A8963</ref-id>
        <pubmed-id>4824499</pubmed-id>
        <citation>Luders H, Lai KW, Hinz KH: [Blood and tissue content of sulfamethazine and sulfaquineoxaline in broilers following medication with drinking water. A contribution to mass medication in poultry]. Zentralbl Veterinarmed B. 1974 Jan-Feb;21(1):110-8.</citation>
      </article>
      <article>
        <ref-id>A8964</ref-id>
        <pubmed-id>22455559</pubmed-id>
        <citation>Gaudin V, Rault A, Verdon E: Validation of a commercial receptor kit Sulfasensor Honey for the screening of sulfonamides in honey according to Commission Decision 2002/657/EC. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2012;29(6):942-50. doi: 10.1080/19440049.2012.668718. Epub 2012 Mar 29.</citation>
      </article>
      <article>
        <ref-id>A8965</ref-id>
        <pubmed-id>22331763</pubmed-id>
        <citation>Ghorab MM, Ragab FA, Heiba HI, El-Gazzar MG, El-Gazzar MG: Synthesis, in-vitro anticancer screening and radiosensitizing evaluation of some new N-(quinoxalin-2-yl)benzenesulfonamide derivatives. Arzneimittelforschung. 2012 Jan;62(1):46-52. doi: 10.1055/s-0031-1295496. Epub 2012 Jan 10.</citation>
      </article>
      <article>
        <ref-id>A8966</ref-id>
        <pubmed-id>21671426</pubmed-id>
        <citation>Kumar P, Companyo R: Development and validation of an LC-UV method for the determination of sulfonamides in animal feeds. Drug Test Anal. 2012 May;4(5):368-75. doi: 10.1002/dta.296. Epub 2011 Jun 14.</citation>
      </article>
      <article>
        <ref-id>A8967</ref-id>
        <pubmed-id>22277081</pubmed-id>
        <citation>Wang L, Wu J, Wang Q, He C, Zhou L, Wang J, Pu Q: Rapid and sensitive determination of sulfonamide residues in milk and chicken muscle by microfluidic chip electrophoresis. J Agric Food Chem. 2012 Feb 22;60(7):1613-8. doi: 10.1021/jf2036577. Epub 2012 Feb 8.</citation>
      </article>
      <article>
        <ref-id>A8968</ref-id>
        <pubmed-id>21840270</pubmed-id>
        <citation>Yu H, Tao Y, Chen D, Wang Y, Huang L, Peng D, Dai M, Liu Z, Wang X, Yuan Z: Development of a high performance liquid chromatography method and a liquid chromatography-tandem mass spectrometry method with the pressurized liquid extraction for the quantification and confirmation of sulfonamides in the foods of animal origin. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2653-62. doi: 10.1016/j.jchromb.2011.07.032. Epub 2011 Jul 30.</citation>
      </article>
      <article>
        <ref-id>A8969</ref-id>
        <pubmed-id>21351294</pubmed-id>
        <citation>Jia A, Hu J, Wu X, Peng H, Wu S, Dong Z: Occurrence and source apportionment of sulfonamides and their metabolites in Liaodong Bay and the adjacent Liao River basin, North China. Environ Toxicol Chem. 2011 Jun;30(6):1252-60. doi: 10.1002/etc.508. Epub 2011 Apr 11.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T4</ref-id>
        <isbn>1584884169</isbn>
        <citation>Yannai, Shmuel (2003). Dictionary of Food Compounds with : Additives, Flavors, and Ingredients. CRC Press LLC.</citation>
      </textbook>
    </textbooks>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.</description>
    <direct-parent>Quinoxalines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Diazanaphthalenes</class>
    <subclass>Benzodiazines</subclass>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzenesulfonamides</alternative-parent>
    <alternative-parent>Benzenesulfonyl compounds</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Organosulfonic acids and derivatives</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Pyrazines</alternative-parent>
    <alternative-parent>Sulfonyls</alternative-parent>
    <substituent>Amine</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenesulfonamide</substituent>
    <substituent>Benzenesulfonyl group</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic sulfonic acid or derivatives</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Organosulfonic acid or derivatives</substituent>
    <substituent>Organosulfur compound</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Pyrazine</substituent>
    <substituent>Quinoxaline</substituent>
    <substituent>Sulfonyl</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002218</drugbank-id>
      <name>Sulfaquinoxaline sodium</name>
      <unii>21223EPJ40</unii>
      <cas-number>967-80-6</cas-number>
      <inchikey>WXUQBKOBXREBBX-UHFFFAOYSA-N</inchikey>
      <average-mass>322.32</average-mass>
      <monoisotopic-mass>322.05004106</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Amides</category>
      <mesh-id>D000577</mesh-id>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Aniline Compounds</category>
      <mesh-id>D000814</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Antiprotozoals</category>
      <mesh-id>D000981</mesh-id>
    </category>
    <category>
      <category>Sulfanilamides</category>
      <mesh-id>D013424</mesh-id>
    </category>
    <category>
      <category>Sulfonamides</category>
      <mesh-id>D013449</mesh-id>
    </category>
    <category>
      <category>Sulfones</category>
      <mesh-id>D013450</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB02362</drugbank-id>
      <name>Aminobenzoic acid</name>
      <description>The therapeutic efficacy of Sulfaquinoxaline can be decreased when used in combination with Aminobenzoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08837</drugbank-id>
      <name>Tetraethylammonium</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Tetraethylammonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08999</drugbank-id>
      <name>Cyclopentamine</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Cyclopentamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The risk or severity of adverse effects can be increased when Sulfaquinoxaline is combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Ketoprofen is combined with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The risk or severity of renal failure can be increased when Sulfaquinoxaline is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00375</drugbank-id>
      <name>Colestipol</name>
      <description>Colestipol can cause a decrease in the absorption of Sulfaquinoxaline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00658</drugbank-id>
      <name>Sevelamer</name>
      <description>Sevelamer can cause a decrease in the absorption of Sulfaquinoxaline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00930</drugbank-id>
      <name>Colesevelam</name>
      <description>Colesevelam can cause a decrease in the absorption of Sulfaquinoxaline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01432</drugbank-id>
      <name>Cholestyramine</name>
      <description>Cholestyramine can cause a decrease in the absorption of Sulfaquinoxaline resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The therapeutic efficacy of Insulin lispro can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The therapeutic efficacy of Insulin glargine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The therapeutic efficacy of Insulin pork can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The therapeutic efficacy of Troglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The therapeutic efficacy of Acarbose can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The therapeutic efficacy of Quinine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The therapeutic efficacy of Miglitol can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The therapeutic efficacy of Nateglinide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The therapeutic efficacy of Pentamidine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The therapeutic efficacy of Mifepristone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The therapeutic efficacy of Repaglinide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The therapeutic efficacy of Phenformin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The therapeutic efficacy of Glyburide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The therapeutic efficacy of Pioglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The therapeutic efficacy of Bromocriptine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The therapeutic efficacy of Mitiglinide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The therapeutic efficacy of Sitagliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The therapeutic efficacy of Sunitinib can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The therapeutic efficacy of Exenatide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The therapeutic efficacy of Mecasermin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The therapeutic efficacy of Pramlintide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The therapeutic efficacy of Glisoxepide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The therapeutic efficacy of Insulin aspart can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The therapeutic efficacy of Insulin detemir can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The therapeutic efficacy of Glymidine can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The therapeutic efficacy of Buformin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The therapeutic efficacy of Voglibose can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The therapeutic efficacy of NN344 can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The therapeutic efficacy of NBI-6024 can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The therapeutic efficacy of AMG-222 can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The therapeutic efficacy of Bisegliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The therapeutic efficacy of Alogliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The therapeutic efficacy of Saxagliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The therapeutic efficacy of Liraglutide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The therapeutic efficacy of Gosogliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The therapeutic efficacy of Canagliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The therapeutic efficacy of Benfluorex can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The therapeutic efficacy of Albiglutide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The therapeutic efficacy of Dulaglutide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The therapeutic efficacy of Netoglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The therapeutic efficacy of Ciglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The therapeutic efficacy of Lixisenatide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The therapeutic efficacy of Insulin beef can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The therapeutic efficacy of Insulin degludec can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The therapeutic efficacy of Insulin tregopil can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The therapeutic efficacy of Dutogliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The therapeutic efficacy of Allicin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The therapeutic efficacy of Bempedoic acid can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The therapeutic efficacy of Teneligliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The therapeutic efficacy of Omarigliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The therapeutic efficacy of Carmegliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The therapeutic efficacy of Gemigliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The therapeutic efficacy of Anagliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The therapeutic efficacy of Evogliptin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The therapeutic efficacy of Balaglitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The therapeutic efficacy of Guar gum can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The therapeutic efficacy of Metahexamide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The therapeutic efficacy of Semaglutide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The therapeutic efficacy of Taspoglutide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The therapeutic efficacy of Englitazone can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The therapeutic efficacy of Tirzepatide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.24</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.61e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>1.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-amino-N-(quinoxalin-2-yl)benzene-1-sulfonamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>sulfaquinoxaline</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>300.336</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>300.068096338</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC1=CC=C(C=C1)S(=O)(=O)NC1=NC2=C(C=CC=C2)N=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H12N4O2S</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H12N4O2S/c15-10-5-7-11(8-6-10)21(19,20)18-14-9-16-12-3-1-2-4-13(12)17-14/h1-9H,15H2,(H,17,18)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NHZLNPMOSADWGC-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>97.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>79.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>29.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>6.79</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>2.13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>8136</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>94719</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D05952</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5147</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Sulfaquinoxaline</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1437847</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>